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The success of proteomics hinges in part on the acting as a specific N-glycosidase that cleaves a single
adenine residue from 28S rRNA [1, 2]. The B subunitdevelopment of approaches able to map receptors
on the surface of cells. One strategy to probe a cell pentamer recognizes a glycolipid receptor, globotriaosyl-
ceramide [3, 4], also known as CD77, Gb3, or Pk antigen.surface for the presence of internalized markers is
to make use of Shiga-like toxin 1 (SLT-1), a Combinatorial SLT-1 libraries were created by randomly
mutating two discontinuous regions of the B subunit. Theribosome-inactivating protein that kills eukaryotic
cells [1, 2]. SLT-1 binds to the glycolipid selection of these regions was based on the following
knowledge. The B subunit is a small protein composedglobotriaosylceramide [3, 4], which acts as a
shuttle, allowing the toxin to be imported and routed of only 69 amino acid residues that pentamerizes sponta-
neously in solution. Structural as well as modeling studiesnear ribosomes. We investigated the use of SLT-1
as a structural template to create combinatorial have indicated that three loop regions of the B subunit
[5, 6] delimited by residues 15–19, 32–35, and 54–64 arelibraries of toxin variants with altered receptor
specificity. Since all SLT-1 variants retain their toxic associated with the receptor binding function of the toxin
(Figure 1; [7–11]). Two dominant classes of binding sitesfunction, this property served as a search engine
enabling us to identify mutants from these libraries for CD77 exist on the B subunit pentamer and are referred
to as sites I and II [7]. Residues located in regions 15–19able to kill target cells expressing internalizable
receptors. Random mutations were introduced in and 30–33, in particular Asp16, Asp17, Phe30, Asn32, and
Arg33 contact the carbohydrate receptor or line the bind-two discontinuous loop regions of the SLT-1
receptor binding subunit. Minimal searches from ing clefts defining sites I and II. The calculated interaction
energy derived from modeling studies suggested that sitescreening 600 bacterial colonies randomly picked
from an SLT-1 library identified toxin mutants able I is likely to be the predominant site mediating CD77
interaction [7], a projection supported by toxin variantsto kill cell lines resistant to the wild-type toxin. One
such mutant toxin was shown to bind to a new harboring mutations at Asp17 and Phe30 [12–16]. In sum-
mary, residues found in loop regions are sites where ran-receptor on these cell lines by flow cytometry. Toxin
libraries provide a strategy to delineate the spectrum dom mutagenesis would lead to an altered receptor speci-
ficity. Toxin libraries were initially constructed withof receptors on eukaryotic cells.
residues randomly mutated at only 9 positions, namely
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panels). The SLT-1 library produced an average amino
acid substitution rate of close to nine out of nine residues
in the target regions, resulting in a potential library diver-
sity of up to 209 SLT mutants (Table 1). Searches throughResults and discussion
Construction of SLT-1 libraries the library were conducted to identify cytotoxic mutants
able to kill these two cell lines. A collection of 600 singleShiga-like toxin 1 (SLT-1) is a ribosome-inactivating pro-
tein composed of two functional domains: a catalytic A clones was selected from the library. Briefly, individual
colonies were picked from a library and their lysatessubunit involved in the blockage of protein synthesis and
a pentamer of identical B subunits (Figure 1). The A chain screened on SLT-1-resistant cell lines. Several clones
were typically able to delete .80% of cells in relation tois responsible for the inactivation of eukaryotic ribosomes,
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Table 1Figure 1
Amino acid sequences of two mutated B subunit loop regions
of SLT-1 variants exhibiting cytotoxic activity against CAMA-1
or PC-3 cells (clones recovered from SLT-1 library).
Loop #1 Loop #2
Clone number (residues 15–19) (residues 30–33)
Wild-type SLT-1 NDDDT FTNR
Search through SLT-1 library/target cell line: CAMA-1
122 CLLNG YQEP
126 QGLQL TLTG
142 TGATM PTGI
241 FRPAG LRCG
308 PYVFL MVAN
324 KSMDQ LSKW
715 QGEYG IQER
823 MVQEK SKKQ
824 DYFQT RHYS
Search through SLT-1 library/target cell line: PC-3
16 MVQEK SKKQ
38 NYMTR LAAI
43 IDEGS TDYA
45 GDRME RRQP
273 GDVTF FMRQ
277 LAVAL QPNL
296 LRYDK PRES
297 YGKPA HTPF
bacterial extracts (individual colonies labeled from 61 to
121) dispensed in wells containing viable PC-3 cells is
presented in Figure 2.
Cytotoxicity curves for toxin mutants derived from the
SLT-1 library are presented in Figure 3. CD50 values
ranging from 50 to 100 nM were calculated for these
SLT-1 variants (variant 122, CD50 80 nM ; variant 126,
CD50 100 nM ; and variant 824, CD50 50 nM). The se-
quences of the mutated inserts present in the variants are
presented in Table 1. No pattern of amino acid conserva-
tion was observed amongst the clones isolated from the
library. Their toxicity was relatively modest in relation to
the potency of the native toxin toward sensitive Vero cells
(Figure 3a, CD50 1.5 fM). A rationale for the lower toxicity
of SLT-1 variants may be linked to a limited expression
of most surface receptors targeted by mutant toxins or
Backbone representations of Shiga toxin [(a), side view] and its B
may reflect the rate of internalization and nature of thesubunit [(b), bottom view] [6]. Shiga and Shiga-like toxin 1 (SLT-1)
intracellular route taken by the targeted receptor. Forhave identical B subunits and differ by a single amino acid substitution
in their A chain. The catalytic A subunit [in magenta, (a)] has its C instance, native SLT-1 binds to a glycolipid (CD77, Gb3),
terminus inserted into a central hole formed by a pentamer of B subunits which is internalized at a faster rate than most glycopro-
(in green). Residues located in two noncontiguous loop regions of
teins. In addition, CD77 allows for the retrograde transportthe B subunit (in red, residues 15–19 and 30–33) implicated in
of the toxin to the ER lumen, where the A chain is able todefining the receptor specificity of the wild-type toxin SLT-1 were
selected as target sites for random mutagenesis. retrotranslocate across the ER membrane near ribosomes.
Finally, isomers of this glycolipid define the routing of
SLT-1 inside cells. More specifically, CD77 (Gb3) iso-
forms associated with toxicity have typically short fattycontrol wells containing viable cells (no toxin present).
Plasmid DNA was recovered and sequenced from isolates acid tails (C16:0 and C18:0) [18, 19]. CAMA-1 cells even-
tually display some sensitivity toward the wild-type toxinthat consistently killed such cells in cytotoxicity assays.
A typical profile of cell cytotoxicity for a sample of 60 (.5 mM).
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Figure 2 chain. Upon examination of the crystal structure, this de-
leted region comprises of a largely exposed loop region
(54–64) followed by a short C-terminal b strand (residues
65–68) that is contacting a strand (residues 9–14) located
on the adjacent B subunit in the pentamer. Western blot
analysis of toxin mutant 273 reveals the presence of both
A and B subunits (see Supplementary material). Interest-
ingly, mutations in the b sheet framework outside the
CDR regions of antibodies have been shown to have a
significant impact on the affinity of the antibody [20].
Flow cytometry reveals the presence of a new receptor
on SLT-1-insensitive cells recognized by a mutant toxin
The binding of toxin variants derived from screening the
SLT-1 library on PC-3 cells were monitored by flow cy-
tometry using an anti-B chain antiserum recognizing a
nonmutated region of the B subunit (residues 26–29; [21]).
Three cell lines were monitored for the expression of
receptors for wild-type and mutant toxins on their surface:Scatter plot displaying a representative set of data collected from
CAMA-1 and PC-3 cells, which were resistant to wild-testing 60 randomly selected toxin variants derived from the library
for their ability to kill PC-3 cells. The relative cytotoxicity (open circles) type SLT-1 and do not express its receptor, and Vero cells,
of individual clones toward PC-3 cells (listed as clones 61 to 121 which display CD77 on their surface and are sensitive to
along the abscissa in this case) was calculated in relation to wells the action of the native toxin (Figures 3a and 4). Wild-containing cells treated with extracts derived from bacteria
type SLT-1 and the mutant 273 were the only toxinsuntransformed with the library. Toxin variants corresponding to wells
showing cytotoxicity .80% (arrow) were chosen for further analysis. tested for which the binding to cells could be detected
The toxicity of cell extracts containing wild-type SLT-1 typically varied by flow cytometry (Figure 4). Cytometric profiles shown
between 2% and 10% . in Figure 4 (left panels) confirmed that CAMA-1 as well
as PC-3 cells did not express SLT-1 receptors on their
surfaces, in contrast to Vero cells, which were strongly
positive for the binding of the native toxin. In comparison,A significant proportion of clones examined in the SLT-1
library were found to contain mutations (including dele- histograms arising from the detection of mutant 273 (Fig-
ure 4; right side panels) illustrate the presence of a newtions) outside the target areas. A clone from SLT-1, clone
273, that was found to retain strong specificity for PC-3 surface receptor recognized by mutant 273 on both
CAMA-1 and PC-3 cells. Interestingly, Vero cells weaklycells in repeated assays was found, when sequenced, to
have a deletion at the C terminus of its B subunit corre- express this new receptor, a finding that may explain its
weak sensitivity to the mutant toxin (Figure 3B).sponding to residues 53–67 of the 69 amino acid-long
Figure 3
Cytotoxicity curves showing the ability of wild-
type SLT-1 and variants identified from the
library to kill target cells. (a) Dose-dependent
cytotoxicity of three SLT-1 variants and of
wild-type SLT-1 screened against CAMA-1
cells: clone 122 (open squares), clone 126
(open triangles), clone 824 (open circles), and
wild-type SLT-1 (closed squares). A curve
showing the sensitivity of CD77-expressing
Vero cells to wild-type SLT-1 (closed circles)
is presented as a control. (b) Dose-dependent
cytotoxicity of a SLT-1 variant (mutant 273)
toward Vero cells (closed boxes), PC-3 cells
(open squares), and CAMA-1 cells (open
circles). Results are given as the percentage
of viable cells in wells treated or not treated
with a toxin. Values represent the average of
experiments performed in triplicate.
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Figure 4
Detection of a cell surface receptor on PC-3
and CAMA-1 cells by a SLT-1 variant (mutant
273) that is distinct from the receptor
recognized by wild-type SLT-1. Flow
cytometric profiles of Vero, PC-3, and
CAMA-1 cells either unstained (left side
panels, solid lines) or stained with the
fluorescein-labeled B subunit of wild-type
SLT-1 (left side panels, dashed lines) are
shown. Cytometric histograms on the right
side highlight the same set of cells labeled
with mutant SLT-1 273. The presence of
bound mutant 273 was detected with a rabbit
anti-MAP peptide antiserum directed at a
nonmutated region of the B subunit followed
by a fluorescein-labeled goat anti-rabbit Ig
antibody. Profiles depict the fluorescence
intensity distributions for cells treated
(dashed lines) or not treated (solid lines) with
the anti-MAP antiserum. Vero cells express
the receptor for the native toxin, while PC-3
and CAMA-1 do not. A new surface receptor
is targeted by mutant 273 on PC-3 and
CAMA-1 cells.
Clues to the nature of the receptor identified sults observed using the more stringent selection process
by mutant 273 based on cytotoxicity searches, where the strong selectiv-
The receptor recognized by mutant 273 is not related to ity pressure imposed on cells by the chronic presence of
the native toxin receptor CD77 (Gb3, globotriaosylcera- the native SLT-1 molecule would have deleted any cells
mide) or to Gb4 (globotetraosylceramide), its closest struc- expressing CD77 or internalized homologs. The disaccha-
tural homolog in the biosynthesis pathway of glycolipids. ride moiety Gala1–4Galb represents the dominant feature
This conclusion is supported by the fact that the target of the receptor recognized by the native toxin [3, 22] and
cell lines have been grown and maintained at all times has been uniquely associated with glycolipid synthesis
in the presence of the native toxin, a precaution to ensure pathways [23] rather than glycoproteins. Western blot
that the native receptor would not be targeted on these analyses performed on membranes derived from PC-3
cell lines. It has been well established that cells expressing cells using mutant 273 and detected using a second anti-
even small levels of CD77 (Gb3) remain very sensitive to body directed at either the A or B chain, did not identify
the native toxin (CD50 values in the pM to fM range; a membrane component acting as the receptor. These
Figure 3a; [17]). Furthermore, an average of nine muta- results would suggest that the putative receptor is a pro-
tions have been introduced in the receptor binding region tein denatured under the conditions of SDS PAGE rather
of the B subunit, indicating that multiple positions de- than a sugar component resembling Gal a1–4Galb [3]. In
fined by site-specific mutagenesis as essential for the summary, our data suggest that the new receptor recog-
recognition of either Gb3 or Gb4 [12–16] have been simul- nized by mutant 273 is not CD77 (Gb3) or Gb4 but rather
taneously altered, effectively destroying native receptor a new chemical entity that may be labile under denaturing
binding sites for either glycolipids [22]. Finally, the flow conditions. A further characterization of this particular
receptor is not presently essential, since our searches havecytometry data presented in Figure 4 simply confirm re-
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